Table TDI-5. Characteristics of all clients entering treatment: demographics and primary drug at treatment in 2006 or most recent year available [see all tables in this series...]

Part (ii) Primary drug type used by clients (percentage of all clients) and of those, the percentage injecting the drug

Country		Opioids	% inj	Cocaine	% inj	Amphe tamines	% inj	Ecstasy	Halluci nogens	% inj	Cannabis	Others	% Injecting main drug
Bulgaria		97.7	82.9	0.2		0.8					1.1	0.2	80.6
Czech Republic		25.4	85.2	0.2	8.3	58.6	80.4	0.2	0.1		12.7	2.7	69.1
Denmark		43.0	12.9	4.7	6.0	6.4	1.2	0.9	0.1		24.5	20.6	7.6
Germany	(1)	49.8	42.7	6.9	29.4	6.2	1.4		0.2	0.7	29.6	7.4	18.1
Ireland		63.8	44.0	10.8	5.0	0.6		1.8	0.0		20.5	2.5	28.4
Greece		87.8	44.4	2.6	8.9	0.0		0.2	0.0		7.3	2.0	39.3
Spain	(2)	39.3	20.6	46.9	6.1	0.8	2.0	0.5	0.1		10.9	1.6	10.9
France		41.2	25.3	6.6	13.9	0.3	8.6	0.7	0.5	1.1	46.9	3.8	10.4
Italy	(3)	56.7	61.0	24.8	9.7	0.1	15.4	0.4	0.1	15.2	15.7	2.2	37.2
Cyprus		56.8	76.0	15.9	6.0			2.8			24.1	0.4	44.1
Latvia	(4)	39.6		0.4		24.5		0.4	1.3		11.1	22.7	53.5
Lithuania		80.4	78.7	0.1	0.0				0.1	0.0	0.5	18.8	92.7
Luxembourg		79.8	72.1	14.6	56.4	0.5		1.9	30.0		1.9	0.0	65.8
Hungary		15.0	60.3	1.0	11.7	4.4	18.7	2.2	0.5		37.9	39.0	10.3
Malta		76.0	76.0	8.0	31.0			3.0	0.0		12.0	1.0	60.9
Netherlands		22.3	8.3	34.7	0.5	5.9	1.0	0.9	1.2		31.8	3.2	1.9
Austria	(5)	65.8	49.4	6.3	17.7	2.0	1.2	0.7	0.1		20.7	4.3	33.7
Poland	(2)	23.3		0.9		8.9			0.6		3.0	63.3	5.9
Portugal	(4)	76.5		8.5		0.2		0.3	0.4		10.8	3.4	21.2
Romania		69.5	97.9	0.2		0.5	20.0	0.4			3.1	26.4	68.7
Slovenia	(6)	91.1	74.1	1.3	65.8	0.1	0.0	0.2			7.0	0.3	68.3
Slovakia		47.0	85.2	1.2	5.6	24.7	45.3	0.3	0.1		18.0	8.7	50.4
Finland		45.0	83.0			25.0	82.0				18.0	12.0	58.0
Sweden		24.4	61.8	2.7	3.4	34.9	67.0	0.1	0.3		17.0	20.6	45.2
United Kingdom	(7)	65.2	39.8	11.6	4.5	3.5	24.5	0.6	0.1	0.8	15.8	3.2	26.7
Turkey		41.8	50.9	3.8	0.9	0.0		3.8			37.2	13.3	21.4

Notes:

 Data were not available for: Belgium, Estonia, Norway. 

 Injecting as a route of administration is not reported for ecstasy, cannabis and other drugs. 

 When proportion of clients by main drug is 0, ‘% of injectors’ is empty. 

 Others substances include hypnotics and sedatives, volatile substances, other stimulants and other substances.         

 (1) Data on amphetamines include amphetamines and ecstasy. 

 (2) Last data available refer to 2005. 

 (3) Until 2004, ‘all clients’ reported clients continuing in or entering treatment in reported year; 2005 data are conformant with the TDI protocol. 

 (4) Data refer to first treatments. No breakdown for injection use available. 

 (5) Up to 2005 data only refer to clients in substitution treatment, using opioids as primary drug. Since 2006, new data collection has been conducted. 

 (6) Last data available refer to 2004. It includes data for outpatient clients and clients treated in prison. Data for outpatient clients was validated, however data collection for prison clients was still in the process of development, thus figures are underestimated. With effect from next year the process of data validation for prison clients will be implemented.  

 (7) Data relate to the period from 1 April 2005 to 31 March 2006 for the UK. 

 See also ‘General notes for interpreting data’ on the Explanatory notes and help page. 

Sources:

 Reitox national reports 2007 — Standard table 3. See Table TDI-1 for details on sources. 

• Download this data in Excel (.xls) format

(see the help page for information about formats etc.)